相关实验视频

Updated: Jul 15, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

在存在因子VIII和/或埃米齐祖马布的情况下,在血管细胞上生成血栓

Sénadé Atsou¹, Célia Schellenberg², Jeremy Lagrange²

¹Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le KremLin-Bicêtre, France.

Journal of thrombosis and haemostasis : JTH

|September 30, 2023

概括

第八因子 (FVIII) 和埃米齐祖马布增强了动脉细胞上的血栓生成. 然而,刺激的内皮细胞限制了这种效果,而艾米齐祖马布与APCC一起导致了过度的血栓生成.

科学领域:

血液静止和血栓形成
血管生物学血管生物学
药理学药理学是指药理学的学科.

背景情况:

血生成试验通常使用合成脂.
这项研究研究了人类动脉细胞上的血栓生成:大动脉内皮细胞 (hAEC) 和血管光滑肌细胞 (hVSMC).

研究的目的:

评估休息和刺激HAECs和hVSMCs的能力,以支持因子VIII (FVIII) 或埃米齐祖马布介导的血栓生成.
描述这些动脉细胞的促凝和抗凝性质.

主要方法:

对hVSMCs和 hAECs的组织因子 (TF),脂素 (PS) 暴露,TFPI和血栓模块素的分析.
化细胞与含有FVIII,埃米齐祖马布,活性蛋白质复合物缩物 (APCC) 或组合的FVIII缺乏血.

主要成果:

hVSMCs和 hAECs表达TF和PS; hAECs还表达血栓模块素和TFPI,这表明hVSMCs具有前凝性质.
在两种细胞类型上,FVIII和埃米齐祖马布促进了血栓生成,在hVSMCs上更为如此.
刺激的 hAECs 显示由于抗凝固因子增加而减少了FVIII/emicizumab驱动的血栓生成,而 emicizumab 与APCC导致了过度的血栓生成.

结论:

瘤亡因子刺激HAECs增加了前凝和抗凝因子.
刺激HAECs中增强的抗凝剂活性限制了FVIII和埃米齐祖马布的疗效.
当艾米齐祖马布与APCC结合使用时,可以克服这种限制,从而导致过度的血栓生成.

关键词:

艾米奇祖马布 (Emicizumab) 是一种药物.内皮细胞是内皮细胞.第八个因子的因素.顺肌细胞是平滑肌肉的细胞.产生血栓的发生.

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...